Pfizer Inc (PFE) Announces Positive Results from BREAKWATER Trial

​Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced positive results from its key BREAKWATER trial, which is testing BRAFTOVI in combination with cetuximab and FOLFIRI in patients with metastatic colorectal cancer.

Management noted that the combination showed significant PFS improvement and better overall survival. Although the overall survival was a secondary descriptive endpoint, without statistics, it showed clinically meaningful prolonged improvement with the BRAFTOVI regimen.

​Jeff Legos, Chief Oncology Officer, Pfizer, noted:

“These results build on the positive objective response rate data we recently shared, providing further evidence of the meaningful benefit this BRAFTOVI-based targeted approach may offer patients with BRAF V600E–mutant metastatic colorectal cancer.”

​The combination is not yet approved by the FDA. Management plans to submit detailed results for presentation at an upcoming meeting with the FDA.

That said, recently, on February 12, Narumi Nakagiri from Daiwa downgraded Pfizer Inc. (NYSE:PFE) from Buy to Hold with a $27 price target. Earlier, on February 10, Courtney Breen from Bernstein reiterated a Hold rating on the stock with a price target of $30.

​Breen from Bernstein noted that the company posted earnings beat during fiscal Q4 2025 earnings. Revenue for the quarter came in at $17.6 billion, surpassing estimates by 6%, and EPS came in at $0.66, topping consensus by 16%. However, the analyst highlighted that Pfizer has made some big bets in terms of R&D investments and oncology pipeline development. The firm sees 2026 as the year where these choices will play out; Bernstein maintains a Hold rating.

​Pfizer Inc. (NYSE:PFE) operates as a research-driven global biopharmaceutical company, developing and commercializing medicines across oncology, primary care, and specialty areas for patients around the world.